Form 4: Olema Pharmaceuticals Director Executes Intra-Fund Share Transfer
SEC Form 4 Filing
Graham G. Walmsley, a director at Olema Pharmaceuticals, executed an intra-fund transfer of 700,761 common shares between two Logos funds he manages.
Summary
- Graham G. Walmsley, a director of Olema Pharmaceuticals, reported a transaction involving the transfer of 700,761 common shares.
- The shares were transferred from Logos Opportunities Fund I LP to Logos Opportunities Fund IV LP.
- Both funds are under the common control of Mr. Walmsley.
- The transaction occurred on December 17, 2024, at a price of $6.75 per share.
- Following the transaction, Mr. Walmsley indirectly controls 1,408,875 shares through these funds.
- Mr. Walmsley disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for an intra-fund transfer, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine SEC Form 4 filing related to insider transactions, which is common for publicly traded companies. The transaction is an internal transfer between funds managed by the same individual and does not represent a change in overall ownership by the reporting person.
Comparison to Industry Standards
- SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
- The intra-fund transfer is not unusual and is often part of portfolio management strategies.
- The transaction is similar to other insider transactions reported by directors and officers of publicly traded companies.
Related Party Transactions
- The transaction is between two funds managed by the same individual, Graham G. Walmsley, making it a related party transaction.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders as it is an internal transfer and does not change the overall ownership by the reporting person.
Key Dates
| Date | Description |
|---|---|
| 12/13/2024 | Date of earliest transaction reported on the form. |
| 12/17/2024 | Date of the share transfer transaction and the date the form was signed. |
Keywords
Olema Pharmaceuticals, Graham G. Walmsley, share transfer, insider transaction, Logos Opportunities Fund, common stock, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.